Safety of dabigatran etexilate for the secondary prevention of venous thromboembolism in children
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61988987%3A17110%2F20%3AA2102940" target="_blank" >RIV/61988987:17110/20:A2102940 - isvavai.cz</a>
Alternative codes found
RIV/00216224:14110/20:00116026 RIV/65269705:_____/20:00072665 RIV/00843989:_____/20:E0108389 RIV/00064203:_____/20:10412680
Result on the web
<a href="https://watermark.silverchair.com/bloodbld2019000998.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAA8UwggPBBgkqhkiG9w0BBwagggOyMIIDrgIBADCCA6cGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMZD0RPuAbrKSWgwAdAgEQgIIDeOb4wxLbO_zM6MIH9Z5f3tpX6pzgMkAtmd1" target="_blank" >https://watermark.silverchair.com/bloodbld2019000998.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAA8UwggPBBgkqhkiG9w0BBwagggOyMIIDrgIBADCCA6cGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMZD0RPuAbrKSWgwAdAgEQgIIDeOb4wxLbO_zM6MIH9Z5f3tpX6pzgMkAtmd1</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1182/blood.2019000998" target="_blank" >10.1182/blood.2019000998</a>
Alternative languages
Result language
angličtina
Original language name
Safety of dabigatran etexilate for the secondary prevention of venous thromboembolism in children
Original language description
This open-label, single-arm, prospective cohort trial is the first phase 3 safety study to describe outcomes in children treated with dabigatran etexilate for secondary venous thromboembolism (VTE) prevention. Eligible children aged 12 to <18 years (age stratum 1), 2 to <12 years (stratum 2), and >3 months to <2 years (stratum 3) had an objectively confirmed diagnosis of VTE treated with standard of care (SOC) for ‡3 months, or had completed dabigatran or SOC treatment in the DIVERSITY trial (NCT01895777) and had an unresolved clinical thrombosis risk factor requiring further anticoagulation. Children received dabigatran for up to 12 months, or less if the identified VTE clinical risk factor resolved. Primary end points included VTE recurrence, bleeding events, and mortality at 6 and 12 months. Overall, 203 children received dabigatran, with median exposure being 36.3 weeks (range, 0-57 weeks); 171 of 203 (84.2%) and 32 of 203 (15.8%) took capsules and pellets, respectively. Overall, 2 of 203 children (1.0%) experienced on-treatment VTE recurrence, and 3 of 203 (1.5%) experienced major bleeding events, with 2 (1.0%) reporting clinically relevant nonmajor bleeding events, and 37 (18.2%) minor bleeding events. There were no on-treatment deaths. On-treatment postthrombotic syndrome was reported for 2 of 162 children (1.2%) who had deep vein thrombosis or central-line thrombosis as their most recent VTE. Pharmacokinetic/pharmacodynamic relationships of dabigatran were similar to those in adult VTE patients. In summary, dabigatran showed a favorable safety profile for secondary VTE prevention in children aged from >3 months to <18 years with persistent VTE risk factor(s). This trial was registered at www.clinicaltrials.gov as #NCT02197416. (Blood. 2020;135(7):491-504) © 2020 by The American Society of Hematology
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30205 - Hematology
Result continuities
Project
—
Continuities
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju
Others
Publication year
2020
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Blood
ISSN
0006-4971
e-ISSN
—
Volume of the periodical
135
Issue of the periodical within the volume
7
Country of publishing house
US - UNITED STATES
Number of pages
14
Pages from-to
491-504
UT code for WoS article
000522643100005
EID of the result in the Scopus database
—